Earnings cover barely half the dividend — book slipping, strategy shifting. Second-quarter net income of $0.23 a share covered 58% of the $0.40 quarterly dividend, and the first quarter was thinner still at $0.16 — $0.39 of earnings against $0.80 declared for the first half, a 6% annualized return on common equity in the second quarter against a 22.7% headline yield. Book value fell for a second straight quarter, from $15.25 at December 31, 2025 to $14.98 at March 31 and $14.83 at June 30, 2026, while the shares traded near $7 — about half of book. Management is answering by shifting equity toward private-label securitization credit and selling $13 billion of mortgage servicing rights unpaid principal balance, but that realignment has not yet closed the earnings gap. No return-of-capital funding of the payout was verified, so this is a warning and an ambiguous trap candidate to watch — not a trap verdict.
Key risk: Mortgage servicing rights runoff and credit-sensitive marks — lower contributions from credit-sensitive strategies drove the second-quarter shortfall, and about 60% of equity was deployed to servicing rights and agency credit-risk-transfer investments. If the servicing-rights sale and securitization shift stall, earnings stay below the dividend.
Changes if: Net income stays below the $0.40 quarterly rate, book value falls for a third straight quarter, or the servicing-rights sale and private-label shift fail to lift the return on equity toward the dividend rate.
- ✗Earnings coverage check Second-quarter net income of $0.23 a share against a $0.40 dividend, and $0.39 against $0.80 for the first half — the dividend is running at roughly double current earnings, and the gap is not a one-quarter event.
- !Book-value check Book value fell from $15.25 at December 31, 2025 to $14.98 at March 31, 2026 and $14.83 at June 30, 2026 — a slow, steady leak while the dividend was held flat, and the market prices the shares at roughly half of book.
- !Strategy and leverage check Management agreed in June 2026 to sell $13 billion of servicing-rights unpaid principal balance and stopped acquiring agency-eligible loans through correspondent production, redeploying into private-label subordinate bonds with low-to-mid-teens return potential — a real plan, but one whose earnings have not yet arrived.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.